Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Srinivasa R, Sanikommu"'
Autor:
Teodora Kuzmanovic, Bhumika J. Patel, Srinivasa R. Sanikommu, Yasunobu Nagata, Hassan Awada, Cassandra M. Kerr, Bartlomiej P. Przychodzen, Babal K. Jha, Devendra Hiwase, Deepak Singhal, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Hetty E. Carraway, Mikkael A. Sekeres, Sudipto Mukherjee, Jaroslaw P. Maciejewski, Tomas Radivoyevitch
Publikováno v:
Haematologica, Vol 105, Iss 3 (2020)
Externí odkaz:
https://doaj.org/article/f2f20fbf1c004806942e297036a8c6ec
Autor:
Thomas G. Knight, Melissa Aguiar, Myra Robinson, Allison Morse, Tommy Chen, Rupali Bose, Jing Ai, Brittany K. Ragon, Aleksander L. Chojecki, Nilay A. Shah, Srinivasa R. Sanikommu, James Symanowski, Edward A. Copelan, Michael R. Grunwald
Publikováno v:
JCO Oncology Practice. 18:e1494-e1504
PURPOSE: Patients with hematologic malignancies are extremely vulnerable to financial toxicity (FT) because of the high costs of treatment and health care utilization. This pilot study identified patients at high risk because of FT and attempted to i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89dd1ce38b1e48f4debe3dc157bc215
https://doi.org/10.1200/op.22.00056
https://doi.org/10.1200/op.22.00056
Autor:
Jing Ai, Brittany K. Ragon, Srinivasa R. Sanikommu, Michael R. Grunwald, Edward A. Copelan, Kristyn Y. DiSogra, Thomas G. Knight, Nilay A. Shah, Ariel Denson, Belinda R. Avalos, Aleksander L. Chojecki, Justin Arnall
Publikováno v:
Blood. 136:14-17
Introduction Gleevec, Imatinib mesylate, is the first in class BCR-ABL tyrosine kinase inhibitor initially approved to treat CML. In February 2016, generic imatinib products became available. As generic products are not required to offer comparative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a73af1ff6eba0248f64002bfa3993fc0
https://doi.org/10.1182/blood-2020-137250
https://doi.org/10.1182/blood-2020-137250
Autor:
Teodora Kuzmanovic, Jaroslaw P. Maciejewski, Deepak Singhal, Yasunobu Nagata, Devendra K Hiwase, Aziz Nazha, Hetty E. Carraway, Bhumika J. Patel, Srinivasa R. Sanikommu, Aaron T. Gerds, Mikkael A. Sekeres, Hassan Awada, Anjali S. Advani, Sudipto Mukherjee, Tomas Radivoyevitch, Cassandra M Kerr, Bartlomiej P Przychodzen, Babal K. Jha
Publikováno v:
Haematologica. 105:e98-e101
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d83c290721782e0dc5cb2a361db01a7
https://doi.org/10.3324/haematol.2019.219352
https://doi.org/10.3324/haematol.2019.219352
Autor:
Ryan Jacobs, Jing Ai, Olivia Copelan, Brittany K. Ragon, Zainab Shahid, James T. Symanowski, Jiaxian He, Saad Z. Usmani, Michael R. Grunwald, Nilanjan Ghosh, Thomas G. Knight, Jigar Trivedi, Srinivasa R. Sanikommu, Peter E. Clark, Candace Butler
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:785-790
Hemorrhagic cystitis (HC) is a common and important complication of allogeneic hematopoietic cell transplantation (HCT). Reactivation of BK virus is its most common cause. The more intense immunosuppressive regimens administered to recipients of graf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56bbebde0c0f3e2a3c7dd94e7c0cc1f
https://doi.org/10.1016/j.bbmt.2018.12.142
https://doi.org/10.1016/j.bbmt.2018.12.142
Autor:
Aleksander L, Chojecki, Justin, Arnall, Danielle, Boselli, Rushil, Patel, Zane, Chiad, Kristyn Y, DiSogra, Allison, Karabinos, Tommy, Chen, Adilen, Cruz, Allison, Verbyla, Jing, Ai, Thomas G, Knight, Brittany K, Ragon, Nilay A, Shah, Srinivasa R, Sanikommu, James, Symanowski, Belinda R, Avalos, Edward A, Copelan, Michael R, Grunwald
Publikováno v:
Leukemia Research. 119:106904
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a2efa40498f2dc6f67abe8a31cdbbf
https://doi.org/10.1016/j.leukres.2022.106904
https://doi.org/10.1016/j.leukres.2022.106904
Autor:
Emily S. Reese, Jiaxian He, Lawrence J. Druhan, Ryan Jacobs, Edward A. Copelan, Candace Butler, Carlos Lee, James T. Symanowski, Belinda R. Avalos, Nilanjan Ghosh, Jing Ai, Saad Z. Usmani, Bei Hu, Manisha Bhutani, Jigar Trivedi, Srinivasa R. Sanikommu, Peter M. Voorhees, Shebli Atrash, Omotayo Fasan
Publikováno v:
Journal of clinical apheresisREFERENCES. 36(4)
Administration of plerixafor with granulocyte-colony stimulating factor (G-CSF) mobilizes CD34+ cells much more effectively than G-CSF alone, but cost generally limits plerixafor use to patients at high risk of insufficient CD34+ cell collection base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b33928f525e9380ba110cc460b64679e
https://pubmed.ncbi.nlm.nih.gov/33710672
https://pubmed.ncbi.nlm.nih.gov/33710672
Autor:
Kris Blackley, Thomas Batchelor, Zainab Shahid, Ben Masten, Belinda R. Avalos, Edward A. Copelan, Thomas G. Knight, Laura W. Musselwhite, Jing Ai, Aleksander L. Chojecki, Michael R. Grunwald, Ashley Sumrall, Tamara K. Moyo, Stephanie Murphy, Carly Rivet, Nilay A. Shah, Armida Parala-Metz, Laura Kabrich, Jean Chai, Kelly A. Leonard, Ifeyinwa Osunkwo, Brittany K. Ragon, Declan Walsh, Srinivasa R. Sanikommu, Brian Kersten, Beth York
Publikováno v:
Blood
Background: Patients (pts) with malignancies are at increased risk of morbidity and mortality from COVID-19. Among these pts, some of the higher case fatality ratios (CFR) reported are among pts with myeloid malignancies, ranging from 37 to 50% (Meht
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7364f149f3643a04278fb50723e43d0c
http://europepmc.org/articles/PMC8701538
http://europepmc.org/articles/PMC8701538
Autor:
Brittany K. Ragon, Belinda R. Avalos, Allison Karabinos, Kristyn Y. DiSogra, Jing Ai, Danielle Boselli, Edward A. Copelan, James T. Symanowski, Michael R. Grunwald, Nilay A. Shah, Aleksander L. Chojecki, Justin Arnall, Tommy Chen, Thomas G. Knight, Srinivasa R. Sanikommu
Publikováno v:
Blood. 138:1252-1252
Introduction: Treatment options for newly diagnosed patients (pts) with acute myeloid leukemia (AML) have historically been limited. The combination of a hypomethylating agent and venetoclax (HMA/Ven) has emerged as standard of care treatment for eld
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16f358ddf05b869b3431d32f0c63348c
https://doi.org/10.1182/blood-2021-149811
https://doi.org/10.1182/blood-2021-149811
Autor:
Srinivasa R. Sanikommu, Abraham P. Fong, Guillermo Garcia-Manero, Hamid Sayar, Bart L. Scott, Alison Forgie, Sophia Randolph, Jaume Pons, Michael Byrne, Jessica K. Altman, Shanhong Guan, Feng Jin, Harry P. Erba
Publikováno v:
Blood. 138:2601-2601
Background: Evorpacept is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region designed to enhance the activity of other anti-neoplastic therapies, such as azacitidine (AZA), with minimal additional toxicity. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b072de537b1ef506dee07664f1fe5bbb
https://doi.org/10.1182/blood-2021-146547
https://doi.org/10.1182/blood-2021-146547